EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 15-Dec-2025 18:11 ET (15-Dec-2025 23:11 GMT/UTC)

7-Dec-2025

Lower doses of immunotherapy for skin cancer give better results

Karolinska Institutet
Peer-Reviewed Publication

According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.

Journal: JNCI Journal of the National Cancer Institute

7-Dec-2025

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

University of Miami Miller School of Medicine
Reports and Proceedings

Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

7-Dec-2025

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

University of Texas M. D. Anderson Cancer Center
Meeting Announcement

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression of the CD40 protein as a potential biomarker associated with improved overall survival (OS).

7-Dec-2025

ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

Patients with lower-risk myelodysplastic syndromes (MDS) experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations of azacitidine or decitabine, according to researchers at The University of Texas MD Anderson Cancer Center.

7-Dec-2025

ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, even after prior treatments have failed, according to researchers at The University of Texas MD Anderson Cancer Center.

7-Dec-2025

Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy

American Society of Hematology
Reports and Proceedings

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

7-Dec-2025

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

American Society of Hematology
Reports and Proceedings

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

7-Dec-2025

New findings support a chemo-free approach for treating Ph+ ALL

American Society of Hematology
Reports and Proceedings

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

7-Dec-2025

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

American Society of Hematology
Reports and Proceedings

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition

6-Dec-2025

University of Cincinnati experts present research at annual hematology event

University of Cincinnati
Meeting Announcement

University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6-9 in Orlando.

Meeting: 67th American Society of Hematology (ASH) Annual Meeting and Exposition